13F Pro quality score
Rank #2,858 of 3,068
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
2 transactions in AVXL reported by 1 member of Congress under the STOCK Act, most recent trade Dec 12, 2022. Reported transactions, not recommendations.
ANAVEX LIFE SCIENCES CORP. (AVXL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVXL at 24.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,858 of 3,068 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (1.2) and institutional flow (7.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.0/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of AVXL by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. AVXL trades on the Nasdaq exchange and files with the SEC under CIK 1314052. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVXL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ANAVEX LIFE SCIENCES CORP. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1314052 →